pass ceo baton abbott
perhap best oper posit
close organ sale growth bring growth
rate estim freestyl libr continu glucos monitor cgm
contribut third growth manag express
confid forese outlook guid organ sale growth
impress view given abbott revenu base nearli billion believ
goal achiev believ premium valuat warrant
better expect sale quarter confid outlook rais price
target prior target pe prior ep prior
impli upsid rel current price believ likelihood
signific re-rat pe expans limit bar step-up growth
thought what next meaning stock
libr abbott refrain specif us approv timelin later-than-
expect approv seemingli curb growth still libr import
stock sentiment physician market icgm design libr
improv algorithm option alarm highlight recent edit
journal scienc technolog letter editor titl head-to-head
comparison studi first-day perform factory-calibr cgm
system albeit small studi patient fund abbott
evalu abbott libr cover system libr day
accuraci better view data show libr
improv competit fda approv still expect day
admittedli half year abbott also work next-iter
product approv outsid libr sever product
await regulatori approvala new rf ablat gener chronic pain
perhap releas weekend nan triclip transcathet tricuspid repair
tendyn transcathet mitral replac receiv ce mark
new platform also receiv fda approv
portico transcathet aortic valv fda approv name
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
idc link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight view share high-
qualiti growth asset believ compani
favor mix busi product
geograph perspect see medic devic
busi particularli diabet key driver
growth go forward believ growth profil
upsid case depend sever key factor
strong growth libr alin approv
adopt new product particularli within medic
devic abil drive margin expans
downsid case driven slower libre/alin
sale fx slowdown emerg market inabl
around likelihood healthcar reform
abbott deliv strong quarter organ sale growth
manag guidanc reflect broad strength across busi unit
biggest contributor libr diabet well core laboratori
alin establish also turn double-digit growth ep in-
line street impress y/i abbott expect organ
sale growth adjust ep view guidanc fairli
in-lin expect continu peer group
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
organ sale growth guidanc street/our
expect medic devic epd also better
guidanc in-lin expect manag guid organ sale growth
adjust ep rang bracket street consensu
libr continu growth driver million sale repres
constant currenc organ growth full year libr sale approach billion
abbott estim current user base million
establish sale expect driven
strong perform sever geographi latin america asia emerg
market sale india brazil russia china sever other
laboratori grew organ constant currenc basi owe
strength alin continu roll-out europ
mitraclip sale constant currenc organ basi abbott
expect receiv expand reimburs initi new
clinic trial expand indic includ moder surgic risk patient
tax rate lower expect help off-set higher sg
libr approv remain outstand manag provid much clariti
around issu timelin approv comment encourag
progress still expect icgm design
sale constant currenc organ basi
gross margin y/i
sg margin y/i margin y/i
adjust tax rate y/i mgmt full year guidanc
abbott expect organ sale growth around organ basi expect follow division/product area
establish pharma epd mid-to-high single-digit growth nutrit expect grow diagnost expect grow mid-to-
high single-digit medic devic expect grow double-digit similar last year fx expect littl
headwind gross margin expect somewhat expect somewhat sale sg around
sale abbott expect ep reflect growth midpoint time earn releas street
estim
abbott expect organ sale growth reflect expect epd sale growth mid-to-high singl digit
nutrit around diagnost mid-to-high single-digit medic devic double-digit similar last year fx
expect neg impact sale ep guidanc bracket consensu
actualsal laboratori management impact chang barclay abbott laboratori
compani report exclud sale
addit commentari abbott call pleas see note
kstew call note mile white comment leav abbott perhap best posit
model pleas see barclay websit link
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
